Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 08/26 10:00:00 pm
79.77 USD   -0.39%
01:07a GILEAD SCIENCES : Canada Pension Plan Investment Board buys $506,849..
08/23 GILEAD SCIENCES : Kelly A. Kramer Joins Gilead Sciences’ Board..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitio..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Sciences : Canada Pension Plan Investment Board buys $506,849,018 stake in Gilead Sciences (GILD)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/27/2016 | 01:07am CEST

Gilead Sciences (GILD) : Canada Pension Plan Investment Board scooped up 1,406,658 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 6,362,654 shares of Gilead Sciences which is valued at $506,849,018.Gilead Sciences makes up approximately 1.94% of Canada Pension Plan Investment Boards portfolio.

Other Hedge Funds, Including , Azimuth Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 4,102 additional shares and now holds a total of 17,893 shares of Gilead Sciences which is valued at $1,425,356. Gilead Sciences makes up approx 0.12% of Azimuth Capital Managements portfolio.Sandy Spring Bank reduced its stake in GILD by selling 635 shares or 1.7% in the most recent quarter. The Hedge Fund company now holds 36,816 shares of GILD which is valued at $2,935,708. Gilead Sciences makes up approx 0.33% of Sandy Spring Banks portfolio.Rdl Financial Inc reduced its stake in GILD by selling 1,719 shares or 4.43% in the most recent quarter. The Hedge Fund company now holds 37,047 shares of GILD which is valued at $2,967,094. Gilead Sciences makes up approx 2.14% of Rdl Financial Incs portfolio.Wedge Capital Management L L Pnc boosted its stake in GILD in the latest quarter, The investment management firm added 132,175 additional shares and now holds a total of 572,650 shares of Gilead Sciences which is valued at $45,508,496. Gilead Sciences makes up approx 0.50% of Wedge Capital Management L L Pncs portfolio.

Gilead Sciences opened for trading at $81.46 and hit $81.64 on the upside on Tuesday, eventually ending the session at $81.47, with a gain of 0.68% or 0.55 points. The heightened volatility saw the trading volume jump to 82,79,418 shares. Company has a market cap of $107,513 M.

On the companys financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The companys revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The companys management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to Hold on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to Outperform and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to Hold on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

(c) 2016 Cihan News Agency. All right reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
01:07a GILEAD SCIENCES : Canada Pension Plan Investment Board buys $506,849,018 stake i..
08/23 GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
08/23 GILEAD SCIENCES : Kelly A. Kramer Joins Gilead Sciences’ Board of Director..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead&..
08/13 EXPRESS SCRIPTS : A secretive board controls access to prescription drugs for mi..
08/12 GENMAB A/S : Enters Commercial License Agreement with Gilead for DuoBody Technol..
08/08 GILEAD SCIENCES : Publishes 2015 Corporate Social Responsibility Report
08/08 GILEAD SCIENCES : Tata Trusts, Gilead sign MoU on viral hepatitis in India
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/26 CyberArk Software Still Has Hope - Cramer's Lightning Round (8/25/16)
08/25 88 Stock Picks For The Next 30 Years (Or More)
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/24 TESLA STOCK : From 0-60 In 2.5 Years
08/23 Who's Next After Medivation?
Advertisement
Financials ($)
Sales 2016 30 499 M
EBIT 2016 20 177 M
Net income 2016 14 534 M
Debt 2016 5 857 M
Yield 2016 2,32%
P/E ratio 2016 7,52
P/E ratio 2017 7,14
EV / Sales 2016 3,66x
EV / Sales 2017 3,54x
Capitalization 105 678 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 107 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-20.86%106 233
AMGEN, INC.4.87%127 850
CELGENE CORPORATION-9.89%85 728
REGENERON PHARMACEUTIC..-26.27%42 671
VERTEX PHARMACEUTICALS..-23.40%23 963
ACTELION LTD17.62%18 399
More Results